UK markets close in 45 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
297.49+0.06 (+0.02%)
As of 10:45AM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • D
    Dascomb
    I don’t know what I would do without the help of http://bullishstocks.tech. Their watchlists are so well researched and help me make the best possible picks when it comes to investing. Not only do they save me time, but their advice has shown to be tried and true!
  • y
    y
    The stock's technical chart looks as good as one can asked. It is at one month high. Money flow, MACD, moving averages are all solidly positive. Need somebody to ignite it to breakthrough $306, then I could see it make a run towards $330s. Even with all the research findings, the company still generate $0.30 free cash flow for every $1 in revenue, and it has more cash than sales. Not many companies can muster as many positive metrics as VRTX has.
  • S
    Samantha
    MASSIVE order are coming in at the close, huge volume. Large institutions on the move again🤑🚀
  • V
    VirginiaLova
    $CRSP conversation
    On September 27, 2022, the Company and Vertex announced that discussions with the U.S. Food and Drug Administration (“FDA”) have concluded, and the FDA granted exa-cel a rolling review for the potential treatment of sickle cell disease and transfusion-dependent beta thalassemia. The exa-cel biologics licensing application will be submitted for rolling review, beginning in November 2022 and the parties expect the submission to be complete by the end of the first quarter of 2023. Discussions were previously completed with the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency on the data required to support marketing applications for exa-cel and such applications are on track for submission by the end of 2022.

    $Crsp $vrtx $arkg $arkk
  • J
    JIMMY
    OIL film on water VRTX's up------FDA , we need longer data - BLUE goes up---BLUE-- Sickel cell---2 drugs approved - NASH---2 female drugs ????no names ---BLUE-a BUY , SELL VRTX- or buy PUTS--
  • W
    William
    I am long Vrtx, Great pipeline, no debt, just there CF alone is major bullish!! Theres nothing bearish about this company, Ive owned it from 180.00 and I'm not selling!! In my opinion its a 350.00 stock right now because its really not expensive at all. If pipeline goes fairly well, goes way higher, coarse this is my opinion on research, make your own decision, tips are for waiters
  • J
    JEFFREY P
    Worth listening to the Wells Fargo Investor Conference Presentation given earlier today by VRTX CEO.
    While no new clinical trial data was given, the timelines of the more advanced VRTX cliniclal trial programs was confirmed. The end of the presentation included affirmation that company discussions with the FDA regarding the NDA process for approval of the Exacel gene editing therapy program for treatement of Sickle Cell and Beta thallassemia had concluded, had gone well, and that after final submission of required documents, would soon be announced clarifyiing when this treatment would be able to be marketed as a potential curative treatment for these two debilitiating and life shortening genetic diseases. She estimated that Phase 3 clinical trials for treatment of acute pain and AMKD are likely to be completed in 2023 along with next generation once a day CF treatment with VX 121 VX 560 and tezacaftor which may have improved efficacy compared to Trikafta. And VX 880 will be progressing in clinical trials being conducted using full doses of stem cell derived islet cells as treatment both with and without use of an immunoprotective device to determine if the need the for immunosuppression can be eliminated to potentially cure Type 1 DM. Each clinical trial represents a multibillion dollar market opportunity for each disease program. These breakthrough therapies once approved, will change the standard of care for each disease for which they are being developed. This company's most impressive period of growth is coming over the next 3 or 4 years. Good news for patients with these diseases and for shareholders who can see the value being created.
  • D
    Damian
    What is with the after hours action? Some news I have not seen?
  • y
    y
    If VRTX stock doesn't move up much when it has positive news on ctx001 from the FDA, I would worry. So far, the stock's decline has been on acceptable if not below average trading volume. This is positive considering the market's negative mood. I hope the company releases Q3 earnings in Oct. It needs positive news to sustain the stock's positive momentum.
  • M
    Mike
    Someone could make a lot of money selling in the 290s and rebuying right after. Never fails
  • T
    Thirdmeinvestor
    I see an era of biotech outperformance is coming whether or not recession is looming over us. Underperformance of the tech sector in recent months does not translate into the same in the biotech sector. Expected good data from Vertex will power the share price higher. We already saw $VRTX, $REGN, $MRNA, $SGEN, and $ALNY are driving the price of $IBB higher. The last two companies above are also acquisition targets.
  • j
    john
    Vertex wins approval for Orkambi to treat children 12-24 months old according to a SA article that was just sent to me. Curiously no PR from the company that I can find?
  • J
    JEFFREY P
    After Friday's selloff of the market as a whole, VRTX continues to get good support around 280 and the trading channel up to $300 remains in tact with positive clinical trial result news likely to come in the fourth quarter which will hopefully allow the stock to breakthrough the $300 resistance and start making new highs.
  • K
    Kevin
    22% year over year revenue increase and more growth down the road.
  • y
    y
    REGN got good FDA news on its existing drug, and the stock jumps 19%. I'd be happy if VRTX stock can jump just 25% of REGN's jump when FDA gives positive news on CTX001. Granted, CTX001 is much smaller revenue generator compares REGN's Eylea. But Eylea's positive news is about an improvement on existing drug for existing patients. CTX001, if successful, will be a new drug, targeting new market and a strategic one since it's based on gene editing technique.
  • G
    George
    VRTX stock has risen 36.2% this year so far against the industry’s decline of 20.6%.
  • J
    JIMMY
    BLUE-- . VRTX -- will VRTX lower the price to destroy BBLUE---?? what is VRTX's cash ?? burn rate ?? Debt to earnings ??
  • M
    Mike
    Just can’t keep 300.